Study Design and Population
This multicenter, double-blind, randomized clinical trial was conducted at Suzhou Xiangcheng People’s Hospital and 3 other tertiary hospitals in Jiangsu Province, China, from January 22 to October 20, 2022. The study protocol was approved by the ethics committees of all participating hospitals and registered in the Chinese Clinical Trial Registratiy Center on January 21, 2022. Written informed consent was obtained from all patients or their families. This report follows the Consolidated Standards of Reporting Trials (